Liquidia (NASDAQ:LQDA) Stock: Insider Michael Kaseta Sells 18,938 Shares

Key Points

• CFO Michael Kaseta sold 18,938 Liquidia shares at an average price of $28.48, worth approximately $539,354. The transaction occurred under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity awards, leaving him with 340,148 shares.
• Liquidia shares traded at $26.81, near the lower end of their 52-week range of $21.94 to $93.61. Analysts have a consensus “Hold” rating and an average price target of $83.69.
• The company’s latest quarter included $171.68 million in revenue, up 1,842% year over year, but adjusted earnings of $0.74 per share narrowly missed estimates of $0.76.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) CFO Michael Kaseta sold 18,938 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $539,354.24. Following the completion of the transaction, the chief financial officer directly owned 340,148 shares of the company's stock, valued at approximately $9,687,415.04. The trade was a 5.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

LQDA stock traded down $0.86 during trading on Tuesday, hitting $26.81. The company had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average price of $63.40 and a two-hundred day moving average price of $61.76. Liquidia Corporation has a fifty-two week low of $21.94 and a fifty-two week high of $93.61. The company has a market cap of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The firm's revenue for the quarter was up 1842.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.49) EPS. Equities research analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current fiscal year.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently modified their holdings of LQDA. Globeflex Capital L P bought a new stake in shares of Liquidia during the 2nd quarter valued at $175,000. Nykredit A S acquired a new position in Liquidia in the second quarter valued at about $177,000. Hurley Capital LLC lifted its stake in Liquidia by 140.7% in the fourth quarter. Hurley Capital LLC now owns 5,200 shares of the company's stock valued at $179,000 after buying an additional 3,040 shares during the period. Apollon Wealth Management LLC acquired a new position in Liquidia in the first quarter valued at about $247,000. Finally, Archer Investment Corp bought a new position in Liquidia during the first quarter worth about $259,000. Institutional investors and hedge funds own 64.54% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on LQDA shares. Bank of America raised their target price on Liquidia from $79.00 to $92.00 and gave the company a "neutral" rating in a research note on Thursday, August 13th. Needham & Company LLC cut their price target on Liquidia from $110.00 to $72.00 and set a "buy" rating for the company in a report on Thursday, October 1st. BTIG Research downgraded shares of Liquidia from a "buy" rating to a "neutral" rating in a research report on Thursday, October 1st. Royal Bank Of Canada set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. Finally, Raymond James Financial reaffirmed an "outperform" rating on shares of Liquidia in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $83.69.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia's lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.